このページの翻訳は実験的なもので、現在開発中です。お待ちしております！
Hikma Pharmaceuticals マネジメント
マネジメント 基準チェック /24
Hikma Pharmaceuticals'の CEO はRiad Mishlawiで、 Sep2023年に任命され、 の在任期間は 1 年未満です。 の年間総報酬は$ 1.55Mで、 21.5%給与と78.5%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.19%を直接所有しており、その価値は£ 8.63M 。経営陣と取締役会の平均在任期間はそれぞれ0.8年と5年です。
主要情報
Riad Mishlawi
最高経営責任者
US$1.6m
報酬総額
| CEO給与比率 | 21.5% |
| CEO在任期間 | less than a year |
| CEOの所有権 | 0.06% |
| 経営陣の平均在職期間 | less than a year |
| 取締役会の平均在任期間 | 5.1yrs |
経営陣の近況
Recent updates
Is Hikma Pharmaceuticals PLC (LON:HIK) Trading At A 29% Discount?
Apr 24
Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?
Apr 02Hikma Pharmaceuticals PLC's (LON:HIK) Share Price Matching Investor Opinion
Feb 25Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?
Dec 27An Intrinsic Calculation For Hikma Pharmaceuticals PLC (LON:HIK) Suggests It's 43% Undervalued
Dec 12Hikma Pharmaceuticals (LON:HIK) Has A Pretty Healthy Balance Sheet
Sep 19Calculating The Intrinsic Value Of Hikma Pharmaceuticals PLC (LON:HIK)
Sep 01Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?
Jun 21Hikma Pharmaceuticals PLC's (LON:HIK) Intrinsic Value Is Potentially 28% Above Its Share Price
Jun 02Hikma Pharmaceuticals (LON:HIK) Has A Pretty Healthy Balance Sheet
Mar 14Calculating The Intrinsic Value Of Hikma Pharmaceuticals PLC (LON:HIK)
Feb 21Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?
Sep 27Hikma Pharmaceuticals PLC's (LON:HIK) Intrinsic Value Is Potentially 19% Below Its Share Price
Jun 24These 4 Measures Indicate That Hikma Pharmaceuticals (LON:HIK) Is Using Debt Reasonably Well
Jun 06Here's Why Hikma Pharmaceuticals (LON:HIK) Can Manage Its Debt Responsibly
Feb 26Hikma Pharmaceuticals PLC's (LON:HIK) Intrinsic Value Is Potentially 92% Above Its Share Price
Dec 01Is Hikma Pharmaceuticals (LON:HIK) Using Too Much Debt?
Nov 11Is There An Opportunity With Hikma Pharmaceuticals PLC's (LON:HIK) 32% Undervaluation?
Sep 02Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?
Aug 09Hikma Pharmaceuticals PLC (LON:HIK) Shares Could Be 26% Below Their Intrinsic Value Estimate
May 21Hikma Pharmaceuticals (LON:HIK) Seems To Use Debt Quite Sensibly
May 03It's Unlikely That Hikma Pharmaceuticals PLC's (LON:HIK) CEO Will See A Huge Pay Rise This Year
Apr 16How Does Hikma Pharmaceuticals PLC (LON:HIK) Stand Up To These Simple Dividend Safety Checks?
Apr 13Hikma Pharmaceuticals PLC (LON:HIK) Looks Interesting, And It's About To Pay A Dividend
Mar 14Hikma Pharmaceuticals PLC Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Feb 28I Ran A Stock Scan For Earnings Growth And Hikma Pharmaceuticals (LON:HIK) Passed With Ease
Feb 22Is There An Opportunity With Hikma Pharmaceuticals PLC's (LON:HIK) 23% Undervaluation?
Feb 03CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Dec 31 2023 | US$2m | US$333k | US$190m |
報酬と市場: Riadの 総報酬 ($USD 1.55M ) は、 UK市場 ($USD 3.34M ) の同様の規模の企業の平均を下回っています。
報酬と収益: Riadの報酬と会社の業績を比較するにはデータが不十分です。
CEO（最高経営責任者
Riad Mishlawi (60 yo)
less than a year
在職期間
US$1,552,833
報酬
Mr. Riad Ali Mishlawi serves as Chief Executive Officer of Hikma Pharmaceuticals PLC since September 01, 2023 and serves as its Director since September 01, 2023. He had been the President of Injectables s...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Executive Chairman | 17yrs | US$3.57m | 0.38% $ 16.1m | |
| CEO & Director | less than a year | US$1.55m | 0.060% $ 2.5m | |
| Executive Vice Chairman & President of MENA | 18.8yrs | US$2.84m | 0.63% $ 26.3m | |
| Chief Financial Officer | 13.5yrs | データなし | 0.20% $ 8.5m | |
| Chief Information Officer | no data | データなし | データなし | |
| Associate Director of Investor Relations | no data | データなし | データなし | |
| General Counsel | no data | データなし | データなし | |
| Executive Vice President of Corporate Development and M&A | 10.3yrs | データなし | 0.28% $ 11.7m | |
| Chief People Officer | less than a year | データなし | データなし | |
| Executive Vice President of Strategic Planning & Global Affairs | 6.5yrs | データなし | データなし | |
| President of Injectables Business | less than a year | データなし | データなし | |
| Senior Vice President of Corporate Quality Compliance/Health & Safety | less than a year | データなし | データなし |
0.8yrs
平均在職期間
60yo
平均年齢
経験豊富な経営陣: HIKの経営陣は 経験豊富 とはみなされません ( 0.8年の平均在職年数)。これは新しいチームを示唆しています。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Executive Chairman | 17yrs | US$3.57m | 0.38% $ 16.1m | |
| CEO & Director | less than a year | US$1.55m | 0.060% $ 2.5m | |
| Executive Vice Chairman & President of MENA | 18.8yrs | US$2.84m | 0.63% $ 26.3m | |
| Senior Independent Non-Executive Director | 1.7yrs | US$149.27k | データなし | |
| Independent Non-Executive Director | 7.8yrs | US$176.38k | 0.0032% $ 134.3k | |
| Independent Non-Executive Director | 8.3yrs | US$159.69k | 0.0016% $ 66.3k | |
| Non-Executive Director | 18.8yrs | US$116.72k | 0.52% $ 22.0m | |
| Independent Non-Executive Director | 4.2yrs | US$149.85k | 0.0020% $ 85.2k | |
| Independent Non-Executive Director | 1.7yrs | US$127.05k | 0.00045% $ 18.9k | |
| Independent Non-Executive Director | 5.1yrs | US$134.68k | 0.00050% $ 21.0k | |
| Chairman of West-ward Pharmaceuticals | no data | データなし | データなし | |
| Independent Non-Executive Director | 1.8yrs | US$124.98k | データなし |
5.1yrs
平均在職期間
66yo
平均年齢
経験豊富なボード: HIKの 取締役会 は 経験豊富 であると考えられます ( 5年の平均在任期間)。